Abstract. This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Breast Cancer, modified based on the international consultation and conference within the frames of the Central-Eastern European Academy of Oncology. The professional guideline primarily reflects the resolutions and recommendations of the current ESMO, NCCN and ABC5, as well as that of the St. Gallen Consensus Conference statements. The recommendations cover classical prognostic factors and certain multigene tests, which play an important role in therapeutic decision-making. From a didactic point of view, the text first addresses early and then locally advanced breast cancer, followed by locoregionally recurrent and metastatic breast ca...
Nicolae Testemitanu State University ofMedicine and Pharmacy, Chisinau, Republic of Moldova, The 6th...
Primary systemic therapy represents the standard of care for locally advanced breast cancer and has ...
Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70–80% of patien...
This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Brea...
Abstract This text is based on the recommendations accepted by the 4th Hungarian Consensus Conferen...
A panel of international breast cancer experts formulated a declaration of consensus regarding many ...
Primary systemic therapy is increasingly used in the treatment of patients with early-stage breast c...
A panel of international breast cancer experts formulated a declaration of consensus regarding many ...
A panel of international breast cancer experts formulated a declaration of consensus regarding many ...
A panel of international breast cancer experts formulated a declaration of consensus regarding many ...
Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing nu...
Expert consensus-based recommendations regarding key issues in the use of primary (or neoadjuvant) s...
This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Brea...
The management of metastatic breast cancer remains an important and controversial issue. The systemi...
Primary systemic therapy represents the standard of care for locally advanced breast cancer and has ...
Nicolae Testemitanu State University ofMedicine and Pharmacy, Chisinau, Republic of Moldova, The 6th...
Primary systemic therapy represents the standard of care for locally advanced breast cancer and has ...
Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70–80% of patien...
This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Brea...
Abstract This text is based on the recommendations accepted by the 4th Hungarian Consensus Conferen...
A panel of international breast cancer experts formulated a declaration of consensus regarding many ...
Primary systemic therapy is increasingly used in the treatment of patients with early-stage breast c...
A panel of international breast cancer experts formulated a declaration of consensus regarding many ...
A panel of international breast cancer experts formulated a declaration of consensus regarding many ...
A panel of international breast cancer experts formulated a declaration of consensus regarding many ...
Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing nu...
Expert consensus-based recommendations regarding key issues in the use of primary (or neoadjuvant) s...
This text is based on the recommendations accepted by the 4th Hungarian Consensus Conference on Brea...
The management of metastatic breast cancer remains an important and controversial issue. The systemi...
Primary systemic therapy represents the standard of care for locally advanced breast cancer and has ...
Nicolae Testemitanu State University ofMedicine and Pharmacy, Chisinau, Republic of Moldova, The 6th...
Primary systemic therapy represents the standard of care for locally advanced breast cancer and has ...
Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70–80% of patien...